Anbio Biotechnology Class A Ordinary Shares

NNNN | NASDAQ

Price Alert Chart Builder DCF Calculator

$5.59

-$0.09 (-1.58%)

Sep 22, 2026, 11:42 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-1.58%

(1D)

Rating

Updated: Aug 10, 2026

53.2

Fundamentals Strong

Market Sentiment Neutral

Moat Narrow

Full Analysis

Key Statistics

Market Data

Market Cap $245.35M

1D Range

5.47 5.72

52W Range

5.13 51.33

Valuation (TTM)

PE 35.50

PB 8.27

EV/EBITDA 34.17

Valuation (NTM)

Forward PE N/A

Forward PEG 0.29

Price Target N/A

Cash Flow

FCF Yield 0.9%

SBC Adj. FCF Yield 0.9%

SBC Impact N/A

Margins

Gross Margin 86.1%

Operating Margin 66.5%

FCF Margin 23.1%

Growth (CAGR)

Revenue 3Y | 5Y -28.4% | N/A

Dil EPS 3Y | 5Y 32.0% | N/A

FCF 3Y | 5Y -304.7% | N/A

Returns

ROA 28.1%

ROE 27.5%

ROIC 25.5%

Financial Health

Net Cash

$11.9M

Current Ratio 344.31

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers reg...

Sector Healthcare

Industry Medical - Instruments & Supplies

Employees 27

IPO Date Feb 18, 2025

Website www.anbio.com

Fiscal Year January - December

Full Company Profile

Latest News

7 months ago · defenseworld.net

Anbio Biotechnology (NASDAQ:NNNN) vs. Oncocyte (NASDAQ:IMDX) Critical Comparison

Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) are both manufacturing companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability. Profitability This table compares Anbio Biotechnology and Oncocyte's net

7 months ago · defenseworld.net

Head to Head Comparison: Anbio Biotechnology (NASDAQ:NNNN) and Oncocyte (NASDAQ:IMDX)

Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) are both manufacturing companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends. Analyst Ratings This is a breakdown of recent ratings

7 months ago · defenseworld.net

Anbio Biotechnology (NASDAQ:NNNN) & Oncocyte (NASDAQ:IMDX) Financial Review

Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) are both manufacturing companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings. Earnings and Valuation This table compares Oncocyte and Anbio

7 months ago · defenseworld.net

Contrasting Anbio Biotechnology (NASDAQ:NNNN) & Oncocyte (NASDAQ:IMDX)

Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) are both manufacturing companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation. Earnings and Valuation This table compares Anbio Biotechnology and